SciCombinator

Discover the most talked about and latest scientific content & concepts.

CM Gibson, S Korjian, P Tricoci, Y Daaboul, M Yee, P Jain, JH Alexander, PG Steg, AM Lincoff, JJ Kastelein, R Mehran, DM D'Andrea, LI Deckelbaum, B Merkely, M Zarebinski, T Oude Ophuis and RA Harrington
Abstract
-Human or recombinant apolipoprotein A-I (apoA-I) has been shown to increase high-density lipoprotein-mediated cholesterol efflux capacity and to regress atherosclerotic disease in animal and clinical studies. CSL112 is an infusible, plasma-derived apoA-I that has been studied in normal subjects or those with stable coronary artery disease. This study aimed to characterize the safety, tolerability, pharmacokinetics, and pharmacodynamics of CSL112 in patients with a recent acute myocardial infarction.
Tweets*
43
Facebook likes*
1
Reddit*
0
News coverage*
39
Blogs*
1
SC clicks
0
Concepts
Stroke, Coronary artery bypass surgery, Coronary artery disease, Artery, Angina pectoris, Atheroma, Myocardial infarction, Atherosclerosis
MeSH headings
-
comments powered by Disqus

* Data courtesy of Altmetric.com